Opdivo increases overall survival in patients with head and neck cancer, according to study

20 April 2016

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) have shown prolonged survival rates when taking Opdivo (nivolumab) compared to standard treatments, it has been announced.

US pharma major Bristol-Myers Squibb (NYSE: BMY) presented the results of its Phase III, open-label, randomized CheckMate -141 trial of Opdivo in patients with SCCHN at the American Association of Cancer Research annual meeting.

The trial, which evaluated overall survival (OS) as the primary endpoint, revealed that 36% of those who received Opdivo after platinum therapy were still alive after one year compared to 16.6% of those who were treated with methotrexate, docetaxel or cetuximab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK